Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.
- Published In:
- Neuropsychiatric disease and treatment, 19, 811-828 (2023)
- Authors:
- Kanes, Stephen J, Dennie, Lara, Perera, Philip
- Database ID:
- RPEP-07026
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07026APA
Kanes, Stephen J; Dennie, Lara; Perera, Philip. (2023). Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.. Neuropsychiatric disease and treatment, 19, 811-828. https://doi.org/10.2147/NDT.S402831
MLA
Kanes, Stephen J, et al. "Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders.." Neuropsychiatric disease and treatment, 2023. https://doi.org/10.2147/NDT.S402831
RethinkPeptides
RethinkPeptides Research Database. "Targeting the Arginine Vasopressin V1b Receptor System and S..." RPEP-07026. Retrieved from https://rethinkpeptides.com/research/kanes-2023-targeting-the-arginine-vasopressin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.